The Application of fMRI in Early Diagnosis of Alzheimer’s Disease: Current Advances, Challenges, and Future Prospects
DOI:
https://doi.org/10.54097/4nsgkc37Keywords:
Functional magnetic resonance imaging (fMRI), Alzheimer’s disease, early diagnosis, neuroimaging technology.Abstract
Alzheimer’s Disease (AD) is a neurodegenerative disorder primarily affecting the elderly and is a leading cause of dementia. Early diagnosis is crucial for delaying symptom progression and improving patient outcomes. Functional Magnetic Resonance Imaging (fMRI) has emerged as a promising tool for early diagnosis due to its non-invasive nature, high spatial resolution, and ability to detect subtle changes in brain activity. This review explores the fundamental principles of fMRI, its advantages over other imaging modalities like Positron Emission Tomography (PET), and its specific application in the early diagnosis of Alzheimer’s Disease. The ability of fMRI to track dynamic functional connectivity in brain regions associated with memory and cognition, such as the hippocampus, highlights its potential as an early biomarker for AD. Despite these strengths, several challenges hinder the full clinical integration of fMRI, including noise during scanning, motion artifacts, and limitations in differentiating specific cognitive processes from generalized brain activity. This review also discusses the future of fMRI, emphasizing its integration with other imaging technologies like Diffusion Tensor Imaging (DTI) and Electroencephalography (EEG), as well as the potential of machine learning and artificial intelligence (AI) in improving data analysis and diagnostic accuracy. Addressing these challenges and leveraging technological advancements could pave the way for fMRI to become a critical tool in the early diagnosis and personalized treatment of Alzheimer's Disease.
Downloads
References
[1] Joe, E. and J.M. Ringman, Cognitive symptoms of Alzheimer’s disease: clinical management and prevention. bmj, 2019. 367.
[2] Leifer, B.P., Early diagnosis of Alzheimer's disease: clinical and economic benefits. Journal of the American Geriatrics Society, 2003. 51(5s2): p. S281-S288.
[3] Scheltens, P., et al., Alzheimer's disease. The Lancet, 2021. 397(10284): p. 1577-1590.
[4] Matthews, P.M. and P. Jezzard, Functional magnetic resonance imaging. Journal of Neurology, Neurosurgery & Psychiatry, 2004. 75(1): p. 6-12.
[5] Glover, G.H., Overview of functional magnetic resonance imaging. Neurosurg Clin N Am, 2011. 22(2): p133-9, vii.
[6] Wierenga, C., & Bondi, M. (2007). Use of Functional Magnetic Resonance Imaging in the Early Identification of Alzheimer's Disease. Neuropsychology Review, 17, 127-143. https://doi.org/10.1007/s11065-007-9025-y.
[7] Winter, F., Bludszuweit-Philipp, C., & Wolkenhauer, O. (2017). Mathematical analysis of the influence of brain metabolism on the BOLD signal in Alzheimer’s disease. Journal of Cerebral Blood Flow & Metabolism, 38, 304 - 316. https://doi.org/10.1177/0271678X17693024.
[8] Wu, X., Li, R., Fleisher, A., Reiman, E., Guan, X., Zhang, Y., Chen, K., & Yao, L. (2011). Altered default mode network connectivity in alzheimer's disease—A resting functional MRI and bayesian network study. Human Brain Mapping, 32. https://doi.org/10.1002/hbm.21153.
[9] Khatri, U., & Kwon, G. (2022). Alzheimer’s Disease Diagnosis and Biomarker Analysis Using Resting-State Functional MRI Functional Brain Network with Multi-Measures Features and Hippocampal Subfield and Amygdala Volume of Structural MRI. Frontiers in Aging Neuroscience, 14. https://doi.org/10.3389/fnagi.2022.818871.
[10] Logothetis, N.K., What we can do and what we cannot do with fMRI. Nature, 2008. 453(7197): p. 869-78.
[11] Wagner, A.D., Early detection of Alzheimer's disease: An fMRI marker for people at risk? nature neuroscience, 2000. 3(10): p. 973-974.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
